In the following interview, co-author and panel member Benjamin M. Brucker, MD, provides a detailed walkthrough of these guidelines and discusses their practical implications for clinicians.He ...

Former President Joseph R. Biden’s recent diagnosis of metastatic prostate cancer has put prostate health back into the national spotlight. His courage in sharing his diagnosis, particularly at age 82 ...

Panelists discuss the expanding treatment options for BCG-unresponsive high-risk non–muscle-invasive bladder cancer, highlighting the benefits and limitations of FDA-approved therapies like ...

First-line nivolumab (Opdivo) plus ipilimumab (Yervoy) continued to show improved survival and durable response benefits vs sunitinib (Sutent) in patients with previously untreated advanced renal cell ...

Results of subgroup analyses of the phase 3 CREST trial (NCT04165317) evaluating sasanlimab plus BCG compared with BCG alone in patients with high-risk non–muscle invasive bladder cancer (NMIBC) found ...

The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted in a unanimous 0-8 decision that the TALAPRO-2 data on talazoparib (Talzenna) in combination with enzalutamide (Xtandi) is not sufficient to ...

The ODAC meeting was called to discuss the submitted new drug application (NDA) for UGN-102, which the agency previously accepted in October 2024, issuing a Prescription Drug User Fee Act (PDUFA) ...

Former President Joe Biden has been diagnosed with grade group 5 de novo metastatic hormone-sensitive prostate cancer, according to a recent announcement from his office. 1 This diagnosis has raised ...

Landmark randomized trials conducted in the early 2000s demonstrated a survival advantage for up-front cytoreductive surgery in combination with interferon alfa compared with interferon alpha alone, ...

A recent study examined the relationship between randomized controlled trials and real-world efficacy of prostate cancer treatments. 1 Investigators found that benefits of treatments that are observed ...

Findings from an open-label extension trial from the phase 3 COURAGE study (NCT03902080) of vibegron (Gemtesa) revealed that treatment of men with overactive bladder (OAB) symptoms who were receiving ...

At this year’s American Urological Association (AUA) Annual Meeting in Las Vegas, Nevada, the AUA released their new guideline on genitourinary syndrome of menopause in collaboration with the Society ...